Axsome Therapeutics Inc (AXSM) - Total Liabilities
Based on the latest financial reports, Axsome Therapeutics Inc (AXSM) has total liabilities worth $659.02 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AXSM shareholders equity momentum to track the company's year-over-year net asset growth rate.
Axsome Therapeutics Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Axsome Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See AXSM cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Axsome Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Axsome Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Aeroportuario del Pacifico SAB De CV ADR
NYSE:PAC
|
USA | $72.32 Billion |
|
Essential Utilities Inc
NYSE:WTRG
|
USA | $12.08 Billion |
|
Mowi ASA
OL:MOWI
|
Norway | Nkr5.86 Billion |
|
DIETEREN GR. UNSP.ADR 1/2
F:DJD
|
Germany | €6.17 Billion |
|
Harmony Gold Mining Company Ltd
BA:HMY
|
Argentina | AR$22.85 Billion |
|
Dongfang Electric Corp Ltd Class A
SHG:600875
|
China | CN¥117.28 Billion |
|
BUDWEISER BREW.UNSP.ADR/4
F:4BB1
|
Germany | €4.45 Billion |
|
Crown Holdings Inc
NYSE:CCK
|
USA | $10.89 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Axsome Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Axsome Therapeutics Inc (AXSM) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 12.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Axsome Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Axsome Therapeutics Inc (2013–2025)
The table below shows the annual total liabilities of Axsome Therapeutics Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $601.51 Million | +17.60% |
| 2024-12-31 | $511.48 Million | +28.75% |
| 2023-12-31 | $397.26 Million | +79.01% |
| 2022-12-31 | $221.92 Million | +207.56% |
| 2021-12-31 | $72.15 Million | -0.26% |
| 2020-12-31 | $72.34 Million | +72.95% |
| 2019-12-31 | $41.83 Million | +189.64% |
| 2018-12-31 | $14.44 Million | -23.34% |
| 2017-12-31 | $18.84 Million | +13.20% |
| 2016-12-31 | $16.64 Million | +532.29% |
| 2015-12-31 | $2.63 Million | -56.05% |
| 2014-12-31 | $5.99 Million | +45.18% |
| 2013-12-31 | $4.13 Million | -- |
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more